Background: Chronic kidney disease (CKD) recently was identified as a public health problem requiring a public health prevention approach. The National Kidney Foundation Kidney Early Evaluation Program (KEEP), initiated in 2000, meets the definition of a public health program, offering surveillance and early detection of CKD. This report aims to detail demographic characteristics of KEEP participants and compare them with characteristics of participants in the National Health and Nutrition Examination (NHANES) 1999-2004.

Methods: KEEP is a CKD screening program enrolling individuals 18 years and older with a family history of kidney disease or personal or family history of diabetes or hypertension. Simple descriptive statistics were used in the analysis. For comparison, the NHANES sample was restricted to participants with hypertension or diabetes or a family history of hypertension or diabetes.

Results: The number of KEEP participants grew exponentially over time. Most participants were aged 46 to 60 years. KEEP enrolled twice as many women as men (68.4% versus 31.5%). Minorities were well represented (33.4% African American, 12.3% Hispanic). Almost 58% of participants had some college or more education, and close to 85.0% had a physician. Compared with NHANES, the KEEP population was older and included a larger proportion of women and African Americans. Self-reported hypertension, self-reported diabetes, obesity, and CKD were higher in KEEP (52.9% versus 38.5%, 26.6% versus 9.9%, 43.6% versus 35.5%, and 22.8% versus 17.6%, respectively).

Conclusions: KEEP has been successful in enrolling individuals at risk of kidney disease, evidenced by the high levels of self-reported hypertension and diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2007.12.022DOI Listing

Publication Analysis

Top Keywords

kidney disease
12
public health
12
family history
12
kidney early
8
early evaluation
8
evaluation program
8
demographic characteristics
8
characteristics participants
8
enrolling individuals
8
hypertension diabetes
8

Similar Publications

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease often treated with glucocorticoids, which can lead to complications such as osteoporosis and an increased infection risk. Hence, identifying safe and effective treatment strategies is crucial. has shown promise in improving immune disorders.

View Article and Find Full Text PDF

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

Int J Rheum Dis

January 2025

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first-line options.

View Article and Find Full Text PDF

Introduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) is a highly prevalent condition with complications such as constipation, inflammation, and dietary restrictions. Gut microbiota is an ecosystem of trillions of bacteria and other microorganisms such as viruses, fungi, and other eukaryotes. This review aimed to analyze the correlation between CKD and the microbiota.

View Article and Find Full Text PDF

The interplay between multiple organs, known as inter-organ crosstalk, represents a complex and essential research domain in understanding the mechanisms and therapies for kidney diseases. The kidneys not only interact pathologically with many other organs but also communicate with other systems through various signaling pathways. It is of paramount importance to comprehend these mechanisms for the development of more efficient therapeutic strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!